Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1

Interventions

pembrolizumab 5Nivolumab 4Cisplatin 4Paclitaxel 3Ifosfamide 3avelumab 2aldesleukin 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Ipilimumab 2vinflunine 1toripalimab 1rocakinogene sifuplasmid 1niraparib 1nimotuzumab 1lenvatinib 1fludarabine phosphate 1fludarabine 1enfortumab vedotin 1durvalumab 1dostarlimab 1dacomitinib 1cemiplimab 1cabozantinib 1cabazitaxel 1Vorinostat 1VGX-3100 1Specimen Handling 1Ritonavir 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Penile Neoplasms × Adoptive Transfer × Clear all
NCT05686226 2026-02-27

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Rutgers, The State University of New Jersey

Phase 2 Recruiting
20 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡